See every side of every news story
Published loading...Updated

Results from Novadip phase 1b/2a trial reveal 88% efficacy - Pharmafile

Summary by pharmafile.com
Novadip Biosciences, a clinical stage biotechnology company with a specialty in regenerative medicine, has announced the results of its 12-month post-surgical visit as part of phase 1b/2a of the NCT05693558 trial. The trial is to monitor the results of an investigational tissue regeneration product from Novadip, NVD003. The product is derived from adipose stem cells […] The post Results from Novadip phase 1b/2a trial reveal 88% efficacy appeared…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmafile.com broke the news in on Tuesday, January 28, 2025.
Sources are mostly out of (0)